CXA-10

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
CXA-10
Accession Number
DB15026
Type
Small Molecule
Groups
Investigational
Description

CXA-10 is under investigation in clinical trial NCT03422510 (FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)).

Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
1N19AGY57Y
CAS number
875685-46-4
Weight
Average: 327.465
Monoisotopic: 327.240958547
Chemical Formula
C18H33NO4
InChI Key
WRADPCFZZWXOTI-BMRADRMJSA-N
InChI
InChI=1S/C18H33NO4/c1-2-3-4-5-8-11-14-17(19(22)23)15-12-9-6-7-10-13-16-18(20)21/h15H,2-14,16H2,1H3,(H,20,21)/b17-15+
IUPAC Name
(9E)-10-nitrooctadec-9-enoic acid
SMILES
CCCCCCCC\C(=C/CCCCCCCC(O)=O)[N+]([O-])=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0062737
ChemSpider
21375709
BindingDB
50295049
ChEBI
86285
ChEMBL
CHEMBL561371
ZINC
ZINC000040331256

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAcute Kidney Injury (AKI)2
1CompletedTreatmentAcute Kidney Injury (Nontraumatic) / The Indication is Acute Kidney Injury-contrast Induced2
1CompletedTreatmentChronic Kidney Injury1
2Active Not RecruitingTreatmentPrimary Focal Segmental Glomerulosclerosis1
2Active Not RecruitingTreatmentPulmonary Arterial Hypertension (PAH)1
2RecruitingTreatmentAsthma / BMI >30 kg/m21
2RecruitingTreatmentPAH2
2WithdrawnTreatmentAsthma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000774 mg/mLALOGPS
logP5.26ALOGPS
logP5.97ChemAxon
logS-5.6ALOGPS
pKa (Strongest Acidic)4.99ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area80.44 Å2ChemAxon
Rotatable Bond Count16ChemAxon
Refractivity92.77 m3·mol-1ChemAxon
Polarizability39.06 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:43 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates